ADARB2 and glioblastoma: All three protein-coding targets were found to be significantly enriched in the ADAR3 IPs compared with the preimmune IPs from U373 cells (Fig. 1E), suggesting that our RIP-seq approach identified high confidence binding targets of ADAR3 in the glioblastoma transcriptome.